Articles On Neuren Pharmaceuticals (ASX:NEU)

The S&P/ASX 200 Index (ASX: XJO), at risk of sounding like a broken record, hit a new record high once more this Monday, in what was a very encouraging start to the trading week for investors.  By...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

Morgans’ Scott Power describes mood at Bioshares Biotech Summit as “markedly more upbeat than prior years” with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-te...

Highlights ASX eases amid US Federal Reserve developments Gold stocks gain traction as gold prices rise Select large-cap companies show strong momentum The Australian share market traded with a softer tone during midday Friday, wi...

The ASX200 has been trading in the red leading into the close. Industrials, Health Care, and Energy were the poorest performing sectors in afternoon trade. On the green side of things, Real Estate, Discretionary, and Staples all bucke...

The S&P/ASX 200 Index (ASX: XJO) appears to have run out of gas on Thursday after its strong run. In afternoon trade, the benchmark index is down 0.2% to 8,824.6 points. Four ASX shares that are not letting that hold them back are liste...

Neuren’s US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs “with immediate effect”   Despite firming US sales of its Re...

Dual-listed across the Nasdaq composite and the ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as sales of its flagship drug DAYBUE jump +14% on Q2 2024. Listen to the HotCopper podcast for in-dept...

  Highlights Healthcare sector recovers strongly after extended underperformance across the year ASX-listed biotech and diagnostic firms report notable progress and investor interest Global partnerships and advanced tech de...

Highlights Mixed start for Australian equities with notable moves in resources and retail. Small caps continue to show early market activity. Company updates influence investor sentiment. The ASX opened the week with a blend of st...

Rett syndrome is rare but relentless Neuren struck biotech gold with Daybue Neurotech brings cannabis to the fight   Rett syndrome is the kind of diagnosis that hits hard and lingers long. It affects around one in 10,000 girls, and typica...

The S&P/ASX 200 Index (ASX: XJO) pulled back from the new all-time high we saw yesterday this session, recording a slight fall for this Thursday's trading. By the time trading closed, the ASX 200 ha...

Highlights: ASX 200 trims early losses as sectors rebound Viva Energy under pressure after first-half update Lithium and uranium stocks show mixed reactions The ASX 200 began Tuesday’s session in the red, touching earl...

Highlights Fortescue delivers strong Q4 shipment results Healthcare stocks shine despite market weakness Bapcor tumbles after weak trading update The ASX 200 ended the session in negative territory, weighed down by wid...

ASX falls 0.31pc with 10 of 11 sectors down Healthcare moves against the grain, up 1.04pc Fortescue jumps 4.34pc on quarterly results ASX looking poorly by end of trade The ASX 200 stumbled a little today, down 0.31% with 10 of 11 sector...

Big Tech faces earnings test this week JPMorgan warns crowding is off the charts Neuren shows what happens when everyone’s already in   This is one of those weeks where Aussie investors in US tech companies hold their breath and hit refre...

ASX healthcare shares form a core component of many Australian investors' portfolios. They are seen as offering essential services, and are therefore less susceptible to market volatility.  However, not all ASX healthcare stocks are c...

With ASX reporting season approaching soon, Australian investors may be looking for ASX healthcare stocks to add to their portfolio.  Yesterday, the S&P/ASX 200 Index (ASX: XJO) reached a new all-time high of 8,641 points.  The A...

POTUS threatens a foreign drug tariff, but gives Big Pharma more time to shift production onshore ASX drug makers say they won’t be overly affected by any Trump tariff whack Island Pharma acquires a secondary virus program   Donald Trump...

Highlights Clarity Pharmaceuticals tops ASX 300 with double-digit gains Bannerman Energy posts the steepest loss among major decliners Broad-based sector volatility reflects dynamic trading conditions Daily trading on...

Highlights ASX 200 futures hint at a positive weekly finish DroneShield and Neuren Pharmaceuticals impress with strong gains Lithium sector shines as Vanguard’s stake boosts confidence Despite some softness midweek, the Australian...

On Thursday the Australian sharemarket’s benchmark S&P/ASX 200 Index (ASX: XJO) fell 8.4 points, or 0.1 per cent, to 8550.8, with seven out of 11 sectors closing down. The broader All Ordinaries Index (ASX: XAO) slid 6.3 points, to 8773...

Highlights Xero slides on news of a major acquisition, weighing on tech Neuren Pharmaceuticals rises following US patent approval DroneShield and Pointsbet attract interest on contract and M&A news Australian share...

Highlights Xero weakens after confirming acquisition of US-based payments firm Melio Neuren Pharmaceuticals climbs on a new US patent approval Broader ASX 200 index trends lower with mixed sector performances The Austr...

Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent to treat Pitt Hopkins Syndrome (PTHS) with its drug NNZ-2591. Listen to the HotCopper podcast for in-depth discussions and insights on all the bigges...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Thursday and trading lower. At the time of writing, the benchmark index is down 0.2% to 8,540.7 points. Four ASX shares that are not letting that hold them back are listed below. Here's...

The market may be having a subdued start to the day but that hasn't stopped two ASX healthcare stocks from racing higher. Let's see why investors are bidding them higher today: Neuren Pharmaceuticals Ltd (ASX: NEU) The Neuren share price i...

UBS reckons healthcare will fare better than any other ASX sector Bell Potter says Monash IVF has fertile recovery prospects Telix wins FDA usage expansion for prostate cancer imaging     Financial giant UBS has declared that enough is e...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

REA Group Ltd (ASX: REA) shares are down 1.43% on Thursday to $233 while the S&P/ASX 200 Index (ASX: XJO) is down 0.12%. Top broker Macquarie recently released a note about Australian residential listings volumes. The note inclu...

There are a total of 200 shares to choose from on the ASX 200 index. Some are buys, some are holds, and some are best avoided. Knowing the difference between which ones are buys and sells is easier said than done, but thankfully there are b...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

Reece Ltd (ASX: REH) shares have been a reliable investment over the past decade. Despite recent wobbles, during this time, the plumbing parts company has quietly delivered an average total return of approximately 10.2% per annum. This mean...

Today, Macquarie initiated coverage on Neuren Pharmaceuticals Ltd (ASX: NEU) shares, tipping significant upside. Neuren Pharmaceuticals has developed DAYBUE (trofinetide), for which Acadia Pharmaceuticals has a worldwide exclusive distr...

Highlights Karoon Energy and Woodside Energy show strong momentum in the energy sector Clarity Pharmaceuticals and Neuren Pharmaceuticals decline amid sectoral rotation Travel, health care, and tech face downward pressure ac...

Highlights ASX 200 advances, led by strength in financials, technology, and retail Tech stocks like NXT, WTC, and XRO post notable gains Gold stocks retreat, with EVN and NEM facing pressure The S&P/ASX 200 Index r...

MND strips voice and movement from thousands Big Freeze and Neale Daniher lead the national fight Control Bionics tech gives the silent a voice   There’s a reason it’s called the Beast. Motor Neurone Disease (MND) creeps in quietly and sl...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injury Preclinical work has shown a significant reduction in secondary brain injury and cardiac damage CEO James Bonnar spent 15 years a...

ASX health stocks up 1.2% over past five days while the broader market is up 0.8%  HealthCo REIT agrees to short-term partial rent deferral with troubled Healthscope and its receivers New-Zealand-based soft-tissue repair company Aroa Biosu...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

Highlights ASX 200 reaches new short-term high, led by Energy and Information Technology sectors Capstone Copper Corp. (ASX:CSC) and Clarity Pharmaceuticals Ltd (ASX:CU6) among top midday performers Paladin Energy Ltd (ASX:P...

Highlights ASX 200 posts slight gain in a subdued and low-volume session Energy sector gains on project approval, pharmaceuticals lift on US trade ruling Stocks with US and China exposure see limited movement despite tariff...

Highlights: Gains in Wisetech Global, Lovisa, and the major banks lifted the ASX 200 Technology, Energy, and Consumer Discretionary sectors showed strength throughout the session Gold stocks saw notable declines, with Evolut...

It was a very positive session for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Tuesday, with the markets throwing off the caution that they started the week with yesterday. After a sha...

Highlights: Lithium sector slides after China’s EV price reductions by BYD InFocus Group surges after securing iGaming technology partnership Telstra outlines its long-term digital infrastructure and emissions plan The...

 Optiscan’s telepathology streaming software enables surgeons to have secure real-time access to pathologists – no matter where they are in the world 4D Medical’s device probes the lung’s innards without the nasties Painchek signs a US dis...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. In afternoon trade, the benchmark index is up slightly to 8,366.6 points. Four ASX shares that are rising more than most today are listed below. Here's why they are c...

Australia has become well-known for its paediatric drug discovery with several life-altering treatments CSL is a global leader in developing therapies for children with haemophilia and other serious blood disorders Neurotech International...

Highlights Neuren Pharmaceuticals Limited (NEU) is listed under the ASX Healthcare index. The company experienced a recent share price increase but remains down over a twelve-month period. Price-to-earnings ratio reflects ea...